Using a Centralized IRB Review Process in Multicenter Clinical Trials. Guidance for Industry
Rockville, MD: U.S. Food and Drug Administration, 2006 March; 7 p. [Online]. Accessed: http://www.fda.gov/cber/gdlns/irbclintrial.pdf [2006 May 3]
Showing items related by title, author, creator and subject.
Guidance for Industry. Using a Centralized IRB Review Process in Multicenter Clinical Trials. Draft Guidance Unknown author (United States. Food and Drug Administration [FDA]; Good Clinical Practice Program, Office of the Commissioner [OC]; Center for Drug Evaluation and Research [CDER]; Center for Biologics Evaluation and Research [CBER]; Office of Regulatory Affairs [ORA], 2005-03)
Draft Guidance for Industry on Using a Centralized Institutional Review Boards Process in Multicenter Clinical Trials; Availability Unknown author (United States. Food and Drug Administration, 2005-03-28)
Guidance on Reporting Adverse Events to Institutional Review Boards for NIH-Supported Multicenter Clinical Trials Unknown author (National Institutes of Health [NIH] (United States), 1999-06-11)